Page last updated: 2024-08-26

mafosfamide and amifostine anhydrous

mafosfamide has been researched along with amifostine anhydrous in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Douay, L; Giarratana, MC; Gorin, NC; Hu, C1
Bouchet, S; Capizzi, RL; Conlon, J; Douay, L; Giarratana, MC; Gorin, NC; Hu, C1
Bony, V; Jiang, R; Lopez, M1
Gorin, NC1
Bialleck, H; Fauth, F; Hoelzer, D; Martin, H; Mihanovic, B; Sonnhoff, S; Wiesneth, M1

Reviews

1 review(s) available for mafosfamide and amifostine anhydrous

ArticleYear
The potential role of amifostine (Ethyol) in haematological malignancies.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 4

    Topics: Acute Disease; Adult; Amifostine; Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Hematopoietic Stem Cells; Humans; Leukemia; Neoplastic Stem Cells

1996

Trials

1 trial(s) available for mafosfamide and amifostine anhydrous

ArticleYear
Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
    Bone marrow transplantation, 2000, Volume: 25, Issue:8

    Topics: Acute Disease; Adjuvants, Immunologic; Adult; Amifostine; Bone Marrow; Bone Marrow Purging; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukemia; Male; Middle Aged; Stem Cells; Transplantation, Autologous

2000

Other Studies

3 other study(ies) available for mafosfamide and amifostine anhydrous

ArticleYear
Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A Suppl 1

    Topics: Amifostine; Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Leukemia; Neoplastic Stem Cells

1995
Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
    Blood, 1995, Oct-01, Volume: 86, Issue:7

    Topics: Amifostine; Antineoplastic Agents; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Cell Death; Cyclophosphamide; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous

1995
Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
    Progress in clinical and biological research, 1994, Volume: 389

    Topics: Amifostine; Animals; Bone Marrow Purging; Bone Marrow Transplantation; Colony-Forming Units Assay; Cyclophosphamide; Hematopoietic Stem Cells; In Vitro Techniques; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Transplantation, Autologous

1994